Circulating endothelial progenitor cells in malignant gliomas. Clinical article

Journal of Neurosurgery

Volumn 112, Issue 1, 2010, Pages 43-49

  Rafat, Neysan ^a,b   Beck, Grietje Ch ^a   Schulte, Jutta ^a   Tuettenbeg, Jochen ^a   Vajkoczy, Peter ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antiangiogenic therapy; Endothelial progenitor cell; Glioblastoma multiforme; Growth factor; Vessel density

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL STEM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STEM CELL; STEM CELL MOBILIZATION; TUMOR VASCULARIZATION;

ANTIGENS, CD; ANTIGENS, CD34; BLOOD; BRAIN NEOPLASMS; ENDOTHELIAL CELLS; FEMALE; GLIOBLASTOMA; GLYCOPROTEINS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 75749096342     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2009.5.JNS081074     Document Type: Article

References (49)

1. Aicher A, Zeiher AM, Dimmeler S: Mobilizing endothelial progenitor cells. Hypertension 45:321-325, 2005
2. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228, 1999
3. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
4. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18:3964-3972, 1999
5. Barrett T, Brechbiel M, Bernardo M, Choyke PL: MRI of tumor angiogenesis. J Magn Reson Imaging 26:235-249, 2007
6. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
7. Bernsen HJ, van der Kogel AJ: Antiangiogenic therapy in brain tumor models. J Neurooncol 45:247-255, 1999
8. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, et al: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346, 2003
9. Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845, 2006
10. Brem S, Cotran R, Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48:347-356, 1972
11. Burnham EL, Taylor WR, Quyyumi AA, Rojas M, Brigham KL, Moss M: Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am J Respir Crit Care Med 172:854-860, 2005
12. Cao Y, Hong A, Schulten H, Post MJ: Update on therapeutic neovascularization. Cardiovasc Res 65:639-648, 2005
13. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, et al: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16:558-565, 2005
14. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, et al: Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol 24:1449-1453, 2006
15. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG: Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60:1388-1393, 2000
16. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D: Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15:297-310, 2005
17. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 67:3560-3564, 2007
18. Grobholz R, Bohrer MH, Siegsmund M, Jünemann KP, Bleyl U, Woenckhaus M: Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 196:277-284, 2000
19. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593-600, 2003
20. Hlatky L, Hahnfeldt P, Folkman J: Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883-893, 2002
21. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchlor TT: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622, 2007
22. Jin KL, Mao XO, Nagayama T, Goldsmith PC, Greenberg DA: Induction of vascular endothelial growth factor and hypoxia-inducible factor-1alpha by global ischemia in rat brain. Neuroscience 99:577-585, 2000
23. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 97:3422-3427, 2000
24. Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, et al: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624-6628, 2001
25. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, et al: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160, 2000
26. Leon SP, Folkerth RD, Black PM: Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362-372, 1996
27. Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR IV, et al: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25:214-221, 2004
28. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201, 2001
29. Moore XL, Lu J, Sun L, Zhu CJ, Tan P, Wong MC: Endothelial progenitor cells' "homing" specificity to brain tumors. Gene Ther 11:811-818, 2004
30. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
31. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:952-958, 2000
32. Peles E, Lidar Z, Simon AJ, Grossman R, Nass D, Ram Z: Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors. Neurosurgery 55:562-567, 2004
33. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15:339-347, 1995
34. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, et al: Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 25: 296-301, 2005
35. Rafat N, Beck GCh, Peña-Tapia PG, Schmiedek P, Vajkoczy P: Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. Stroke 40:432-438, 2009
36. Rafat N, Hanusch C, Brinkkoetter PT, Schulte J, Brade J, Zijlstra JG, et al: Increased circulating endothelial progenitor cells in septic patients: correlation with survival. Crit Care Med 35:1677-1684, 2007
37. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ: The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol 9:1-22, 2008
38. Roberts HC, Roberts TP, Brasch RC, Dillon WP: Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 21:891-899, 2000
39. Roth Y, Tichler T, Kostenich G, Ruiz-Cabello J, Maier SE, Cohen JS, et al: High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. Radiology 232:685-692, 2004
40. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393-401, 1996
41. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
42. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438, 1999
43. Tuettenberg J, Friedel C, Vajkoczy P: Angiogenesis in malignant glioma - a target for antitumor therapy? Crit Rev Oncol Hematol 59:181-193, 2006
44. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31-40, 2005
45. Urbich C, Dimmeler S: Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95:343-353, 2004
46. Vajkoczy P, Blum S, Lamparter M, Mailhammer R, Erber R, Engelhardt B, et al: Multistep nature of microvascular recruitment of ex vivo-expanded embryonic endothelial progenitor cells during tumor angiogenesis. J Exp Med 197:1755-1765, 2003
47. Vajkoczy P, Menger MD, Vollmar B, Schilling L, Schmiedek P, Hirth KP, et al: Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1:31-41, 1999
48. Yung YC, Cheshier S, Santarelli JG, Huang Z, Wagers A, Weissman I, et al: Incorporation of naive bone marrow derived cells into the vascular architecture of brain tumor. Microcirculation 11:699-708, 2004
49. Zheng PP, Hop WC, Luider TM, Sillevis Smitt PA, Kros JM: Increased levels of circulating endothelial progenitor cells and circulating endothelial nitric oxide synthase in patients with gliomas. Ann Neurol 62:40-48, 2007